

Thomas O Bergmeijer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6176541/publications.pdf>

Version: 2024-02-01

38
papers

1,427
citations

516215

16
h-index

329751

37
g-index

39
all docs

39
docs citations

39
times ranked

2208
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y ₁₂ inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 676-685.	0.7	3
2	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 195-206.	1.0	13
3	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009434.	1.4	14
4	Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. <i>International Journal of Cardiology</i> , 2021, 334, 10-17.	0.8	4
5	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 203-210.	1.4	69
6	Effect of CYP3A4*22 and PPAR- α Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. <i>Genes</i> , 2020, 11, 1068.	1.0	2
7	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
8	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1067-1077.	2.3	32
9	Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 663-665.	1.1	1
10	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	1.1	90
11	Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. <i>Lancet</i> , The, 2020, 395, 1374-1381.	6.3	205
12	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. <i>New England Journal of Medicine</i> , 2019, 381, 1621-1631.	13.9	431
13	Tailored P2Y ₁₂ inhibitor treatment in patients undergoing non-urgent PCI—the POPular Risk Score study. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1201-1210.	0.8	16
14	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
15	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	1.6	22
16	A clinical risk score to identify patients at high risk of very late stent thrombosis. <i>Journal of Interventional Cardiology</i> , 2018, 31, 159-169.	0.5	6
17	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). <i>American Heart Journal</i> , 2018, 198, 152-159.	1.2	24
18	Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy. <i>Pharmacogenomics</i> , 2018, 19, 621-628.	0.6	19

#	ARTICLE	IF	CITATIONS
19	Safety of Ticagrelor Compared to Clopidogrel after Prehospital Initiation of Treatment. TH Open, 2018, 02, e357-e368.	0.7	3
20	The effect of correcting VerifyNow P2Y12 assay results for hematocrit in patients undergoing percutaneous coronary interventions. Journal of Thrombosis and Haemostasis, 2017, 15, 618-623.	1.9	15
21	How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS). Seminars in Thrombosis and Hemostasis, 2017, 43, 439-446.	1.5	9
22	Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis. American Journal of Cardiology, 2017, 119, 1500-1506.	0.7	3
23	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
24	Incidence and Causes for Early Ticagrelor Discontinuation: A "Real-World" Dutch Registry Experience. Cardiology, 2017, 138, 164-168.	0.6	25
25	Perioperative management of antiplatelet treatment in patients undergoing isolated coronary artery bypass grafting in Dutch cardiothoracic centres. Netherlands Heart Journal, 2017, 25, 482-489.	0.3	7
26	The effect of acenocoumarol on the antiplatelet effect of clopidogrel. Thrombosis and Haemostasis, 2015, 114, 708-716.	1.8	3
27	Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and older" rationale and design of the POPular AGE study. American Heart Journal, 2015, 170, 981-985.e1.	1.2	43
28	Higher body weight patients on clopidogrel maintenance therapy have lower active metabolite concentrations, lower levels of platelet inhibition, and higher rates of poor responders than low body weight patients. Journal of Thrombosis and Thrombolysis, 2014, 38, 127-36.	1.0	16
29	The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thrombosis and Haemostasis, 2014, 112, 1174-1181.	1.8	28
30	CYP2C19 genotype"guided antiplatelet therapy in ST-segment elevation myocardial infarction patients" Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal, 2014, 168, 16-22.e1.	1.2	71
31	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. Thrombosis and Haemostasis, 2014, 112, 589-597.	1.8	27
32	Prehospital treatment of ST-segment elevated myocardial infarction patients. Future Cardiology, 2013, 9, 229-241.	0.5	4
33	Pre-hospital diagnosis, triage and treatment in patients with ST elevation myocardial infarction. Heart, 2012, 98, 1674-1678.	1.2	5
34	Value of CYP2C19 *2 and *17 Genotyping in Clinical Practice. Promising but Not Ready Yet. Revista Espanola De Cardiologia (English Ed), 2012, 65, 205-207.	0.4	2
35	Reduction in Platelet Reactivity With Prasugrel 5 mg in Low-Body-Weight Patients Is Noninferior to Prasugrel 10 mg in Higher-Body-Weight Patients. Journal of the American College of Cardiology, 2012, 60, 2032-2040.	1.2	75
36	Valor de la determinaci3n del genotipo de CYP2C19 *2 y *17 en la pr3ctica cl3nica. Prometedor, aunque todav3a no est3 listo. Revista Espanola De Cardiologia, 2012, 65, 205-207.	0.6	7

#	ARTICLE	IF	CITATIONS
37	Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. <i>Heart</i> , 2011, 97, 1239-1244.	1.2	72
38	Platelet Function Testing in Clinical Practice – Experience and Views from Europe and the US. <i>European Cardiology Review</i> , 2011, 7, 203.	0.7	1